Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04271514 · ClinicalTrials.gov registry record · Phase 1
A First-in-Human Study of RPT193 in Healthy Volunteers and Patients With Atopic Dermatitis
A Phase 1 study of Atopic Dermatitis, sponsored by RAPT Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 103
- Enrollment target
- 14
- Study locations
NCT04271514 is a Phase 1 study of Atopic Dermatitis that has completed, run by RAPT Therapeutics. The registered enrollment target is 103 participants, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (83% lower). The trial reports 14 study locations across 11 states.
The verdict
NCT04271514, a Phase 1 study of Atopic Dermatitis, has completed, sponsored by RAPT Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 103 participants
- Enrollment target
- 14
- Study locations
Study Summary
This study is a first-in-human, 3-part, multi-center, Phase 1, randomized, double-blind, placebo-controlled study with RPT193 in up to 64 healthy male and female subjects and 30 male and female patients with atopic dermatitis. RPT193 is an orally-available, potent, and selective antagonist of CCR4.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG RPT193
Study Locations (14)
Florida
- Lenus Research & Medical Group - Miami
- ForCare Clinical Research - Tampa
Louisiana
- DelRicht Research - Baton Rouge
- Clinical Trials Management,LLC - Metairie
Texas
- DermResearch, Inc. - Austin
- Progressive Clinical Research PA - San Antonio
Alabama
- Pinnacle Research Group, LLC - Anniston
Arizona
- Perseverance Research Center LLC - Scottsdale
California
- University Clinical Trials, Inc - San Diego
Indiana
- Dawes Fretzin Clinical Research Group, LLC - Indianapolis
Massachusetts
- MetroBoston Clinical Partners LLC - Brighton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2019-08-12 |
| Est. Completion | 2021-04-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04271514
The ClinicalTrials.gov registry entry for NCT04271514 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 103 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (83% lower). The listed sponsor is RAPT Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Atopic Dermatitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04271514 reports 14 study locations spanning 11 distinct geographic areas - top geographies include Florida, Louisiana, Texas.
Frequently Asked Questions
What is clinical trial NCT04271514 about?
NCT04271514 is a clinical study titled "A First-in-Human Study of RPT193 in Healthy Volunteers and Patients With Atopic Dermatitis". This study is a first-in-human, 3-part, multi-center, Phase 1, randomized, double-blind, placebo-controlled study with RPT193 in up to 64 healthy male and female subjects and 30 male and female patients with atopic dermatitis. RPT193 is an orally-available, potent, and selective antagonist of CCR4.
What is the current status of trial NCT04271514?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 103 participants. The study started on 2019-08-12. Estimated completion is 2021-04-26.
What conditions does trial NCT04271514 study?
This clinical trial studies the following conditions: Atopic Dermatitis.
What interventions are being tested in trial NCT04271514?
The interventions under investigation include: Placebo (DRUG), RPT193 (DRUG).
Who is sponsoring clinical trial NCT04271514?
This trial is sponsored by RAPT Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04271514 being conducted?
This trial has 14 study locations across Alabama, Arizona, California, Florida, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis
RECRUITING · Phase 1
-
Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)
RECRUITING · Phase 1
-
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
RECRUITING · Phase 1
-
A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Single and Multiple Dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 1
-
A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD)
RECRUITING · Phase 1
-
A Study to Learn If the Study Medicine Called PF-08049820 Changes How the Body Processes the Other Study Medicines Called Oral Contraceptives, Midazolam, and Dabigatran in Healthy Adult Female Participants
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.